LivaNova PLC (LIA)
XMUN 
Summary
LIA Chart
LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates
LivaNova (LIVN) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.9 per share a year ago.
Is LivaNova (LIVN) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LivaNova: Robust Fundamentals, Long-Term Growth Potential
LivaNova remains a 'BUY' with a raised price target of $61/share, reflecting strong recent results and long-term growth potential. LIVN delivered double-digit revenue growth, improved margins, and raised guidance, driven by Cardiopulmonary and Neuromodulation segment performance. Despite a 20% short-term return, I see further upside due to robust fundamentals, market expansion, and clinical milestones supporting the investment thesis.
LivaNova PLC (LIA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has LivaNova PLC ever had a stock split?
LivaNova PLC Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Vladimir A. Makatsaria CEO | XMUN Exchange | GB00BYMT0J19 ISIN |
| GB Country | 2,900 Employees | - Last Dividend | - Last Split | 10 Feb 1993 IPO Date |
Overview
LivaNova PLC is a globally recognized medical device company engaged in the design, development, manufacture, and sale of innovative therapeutic solutions. With operations spanning worldwide, the company dedicates itself to improving the lives of patients through its comprehensive product offerings in the medical field. LivaNova operates through three distinct segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support, each targeting specific medical needs and challenges. Established in 2015 and headquartered in London, United Kingdom, LivaNova PLC has firmly positioned itself as a key player in the medical device industry, serving an extensive range of healthcare professionals, including perfusionists, neurologists, neurosurgeons, and physicians, as well as hospitals and medical institutions. The company leverages a combination of direct sales representatives and independent distributors to effectively bring its products to the global market.
Products and Services
- Cardiopulmonary Products
- Neuromodulation Devices
- Advanced Circulatory Support
LivaNova’s Cardiopulmonary segment offers a wide range of products aimed at supporting heart and lung function. These include oxygenators, which are critical for maintaining blood oxygen levels during surgery; heart-lung machines that take over the function of the heart and lungs during cardiac procedures; autotransfusion systems for recycling the patient's own blood; perfusion tubing systems for the management of blood flow and composition; cannulae designed for insertion into the body to withdraw or deliver fluids, and various other connective and supportive products. These are pivotal in cardiopulmonary bypass surgeries and other medical applications where the heart and lungs need external support.
Under the Neuromodulation segment, LivaNova advances in providing solutions for challenging neurological conditions. The prominent offering is the VNS Therapy System, an innovative implantable device designed to deliver electrical impulses to the vagus nerve. This system is used for the treatment of difficult-to-treat depression and drug-resistant epilepsy, showcasing LivaNova’s commitment to addressing complex neurological disorders through advanced technology.
The Advanced Circulatory Support segment bringsto the market temporary life support products. These devices are vital in situations where patients require short-term assistance for their circulatory system. This can include support during high-risk surgeries, in the wake of cardiac events, or while awaiting more permanent treatments. The innovation in this area exemplifies LivaNova’s dedication to providing comprehensive circulatory solutions to critically ill patients.
Contact Information
